Adaptimmune starts Phase I of T cell therapy plus Keytruda

Adaptimmune Therapeutics plc (NASDAQ:ADAP) began a Phase I trial of NY-ESO SPEAR T-cell therapy (ADAP NY-ESO TCR, GSK3377794) plus Keytruda pembrolizumab to treat multiple myeloma (MM).

The open-label, U.S. trial will evaluate safety in up to 20 HLA-A*02-positive patients with relapsed and refractory MM expressing cancer/testis antigen 1B (NY-ESO-1; CTAG1B) and/or cancer/testis antigen 2 (CTAG2; LAGE1; NY-ESO-2). Secondary endpoints include overall response rate (ORR), time to response, duration of response, progression-free survival (PFS) and overall survival (OS)...